U.S. Biotech Stock News

If you are wondering whether Wendy's current share price really reflects what the business is worth, this breakdown will help you connect the recent moves in the stock to what the underlying valuation signals are saying. The share price recently closed at US$7.06, with returns of 2.3% over 7 days, a 2.9% decline over 30 days, a 13.6% decline year to date, and a 42.8% decline over the past year, which may have shifted how investors view both risk and potential upside. Recent coverage around...

Land & Buildings has escalated its activist campaign at First Industrial Realty Trust (NYSE:FR), urging shareholders to vote against the re-election of the current Chairman and a long-serving director at the upcoming annual meeting. The activist investor argues that recent actions by FR, including a share buyback, dividend increase, and addition of a new director, do not fully address what it views as ongoing governance and valuation concerns. Land & Buildings is calling for substantial...

Amtagvi data and pipeline momentum reshape the story for Iovance Biotherapeutics (IOVA) The latest move in Iovance Biotherapeutics (IOVA) has been driven by real world data for its Amtagvi cell therapy that outperformed pivotal trial results, together with growing attention on upcoming NSCLC data and wider pipeline progress. See our latest analysis for Iovance Biotherapeutics. At a share price of $3.47, Iovance has seen a 4.52% 1 day share price return and 37.70% year to date share price...

If you are wondering whether Biogen's current share price reflects its true worth, you are not alone. Many investors are asking whether the stock still offers value after its recent moves. The stock last closed at US$179.90, with a 1 year return of 49.3% but also shorter term moves of a 2.1% decline over 7 days, a 4.4% decline over 30 days, and a modest 1.2% gain year to date. These shifts can change how the market views both its growth potential and risk. Recent news flow around Biogen has...

IREN (NasdaqGS:IREN) is back in focus after its multi billion dollar AI cloud agreements, including a five year deal with Microsoft, sharpened investor attention on the company’s pivot away from Bitcoin mining. See our latest analysis for IREN. After concerns around the US$6b at-the-market equity program and execution risks in its AI pivot led to a roughly 20% slide over a recent five-session stretch, the latest multi billion dollar AI cloud contracts and GPU purchase updates have coincided...

Wondering whether PTC at around US$144 per share offers real value or just noise? This article walks through what the current price may be implying about the business. The stock is up 1.3% over the last 7 days, even though it shows a 11.7% decline over 30 days and a 15.2% decline year to date, with a 3.3% decline over the past year and a 14.2% return over three years. These mixed returns put extra focus on what has been moving sentiment around PTC recently, as investors react to new...

Paramount Skydance has secured $24b in equity funding from Middle Eastern sovereign wealth funds for its planned acquisition of Warner Bros. Discovery (NasdaqGS:WBD). The commitments come from Saudi Arabia's Public Investment Fund, Qatar Investment Authority, and Abu Dhabi's L’imad Holding. A special shareholder meeting and ongoing regulatory reviews are the next milestones for the proposed takeover of WBD. Warner Bros. Discovery, the combined media and entertainment group behind Warner...

Morgan Stanley (NYSE:MS) has launched MSBT, a spot Bitcoin ETF that it issues directly as a major US bank. The ETF carries a 0.14% fee, which is lower than many existing spot Bitcoin ETFs in the US market. The launch expands Morgan Stanley's digital asset offerings, alongside filings for Solana and Ethereum trusts and plans for direct crypto trading. Morgan Stanley, a large US bank and wealth manager, is moving deeper into digital assets with MSBT, a proprietary spot Bitcoin ETF. For...

If you are wondering whether Medtronic at around US$88.65 is a bargain or just fairly priced, you are in the right place for a clear look at what the numbers are saying about its value. The share price has returned 3.0% over the last week, with a 2.9% decline over the past month, a 7.7% decline year to date, a 7.3% return over 1 year, a 20.9% return over 3 years, and a 16.6% decline over 5 years. Taken together, this gives you a mixed picture of recent gains and longer term swings in...

Wondering whether Equifax at US$184.38 is starting to look interesting on price, or if there is a better entry point? This article walks through what the current market value really reflects. The stock has recently shown mixed performance, with a 2.6% move over the past week, a 9.9% decline over 30 days, and returns of 13.9% lower year to date and 17.1% lower over the past year. These moves have kept Equifax in focus for investors who follow business services names and are weighing how...

Virgin Galactic Holdings recently filed a US$1.35 million shelf registration for 555,000 shares tied to its employee stock plan and reported fourth-quarter 2025 sales of US$312,000 alongside a net loss of US$62.72 million. At the same time, the company has reopened US$750,000-per-seat ticket sales and advanced its Delta-class spacecraft toward testing, highlighting a push to align capital, talent and product readiness ahead of a planned return to commercial service. We’ll now examine how the...

Insmed announced that its Phase 2b CEDAR study of brensocatib in adults with moderate to severe hidradenitis suppurativa failed to meet primary or secondary efficacy endpoints, leading the company to halt development of the drug for this indication despite a clean safety profile. An interesting outcome was that placebo patients saw a larger reduction in abscess and inflammatory nodule counts than either brensocatib dose, raising fresh questions about disease variability and trial design in...

Recent bearish coverage around Pfizer (PFE), including a reiterated Underperform rating and concerns about weaker revenue from key products, has weighed on sentiment. At the same time, a paused COVID-19 vaccine trial adds to short term uncertainty. See our latest analysis for Pfizer. Despite the latest bearish commentary and trial pause weighing on sentiment in recent days, Pfizer’s share price shows a 9.1% year to date share price return and a 31.0% total shareholder return over the past...

For readers wondering whether Howmet Aerospace at around US$250 a share still offers value or if most of the opportunity is already priced in, this article walks through the numbers so you can judge for yourself. The stock has returned 4.6% over the last 7 days, while the 30 day return is a 1.6% decline, with the year to date move at 18.1% and the 1 year return at 95.7%. Coverage of Howmet Aerospace often focuses on its role in the capital goods sector and its position within aerospace...

Allegiant Travel (NasdaqGS:ALGT) has received U.S. antitrust clearance for its proposed acquisition of Sun Country Airlines. The Hart Scott Rodino Act waiting period ended early, providing a key regulatory approval for the deal. This clearance removes a major hurdle for combining the two carriers in the U.S. aviation sector. Allegiant Travel focuses on leisure oriented air travel, often serving underserved routes with a low cost model. The green light from U.S. antitrust regulators comes at...

If you are wondering whether Paramount Skydance at around US$10.82 is a bargain or a value trap, this article is for you if you want to understand what the current price really reflects. The stock has moved sharply in the short term, with a 17.0% return over the last 7 days, compared with a 3.3% decline over 30 days and a 17.9% decline year to date. These swings are occurring against the backdrop of ongoing attention on the company following the creation of the combined Paramount Skydance...

Doximity (DOCS) has been back in focus after its latest earnings, where revenue topped expectations, but guidance for the next quarter fell short, prompting a sharp market reaction and renewed questions about its growth trajectory. See our latest analysis for Doximity. That cautious guidance has been a key driver of recent weakness, with a 1 day share price return of 2.84% decline adding to a 30 day share price return of 14.24% decline and a 1 year total shareholder return of 60.68% decline...

Why Barrick Mining Is On Investors’ Radar Today Barrick Mining (NYSE:B) is drawing attention after its recent name change from Barrick Gold Corporation in May 2025, a shift that highlights its broader focus across gold, copper, silver, and energy materials. See our latest analysis for Barrick Mining. The share price has been choppy, with a 2.73% 1 day share price return and a 7.20% 30 day share price decline. However, the 1 year total shareholder return of 131.53% points to strong longer term...

AMC Entertainment Holdings (AMC) is back in focus after reporting record Easter weekend results, with more than 6 million guests and strong food, beverage, and merchandise revenue tied to The Super Mario Galaxy Movie. See our latest analysis for AMC Entertainment Holdings. The record Easter weekend has arrived alongside a sharp short term rebound, with a 7 day share price return of 30.1% and 1 month share price return of 18.6%. However, this sits against a 1 year total shareholder return...

Mid-America Apartment Communities (MAA) is back in focus as analysts update their views, the REIT prepares to report upcoming earnings, and insiders execute planned share sales alongside a recently confirmed quarterly dividend. See our latest analysis for Mid-America Apartment Communities. The recent 1-day share price return of 1.44% and 7-day gain of 2.89% to US$126.09 sit against a weaker backdrop, with a 30-day share price return of 4.58% and a 1-year total shareholder return of 16.66%...

If you are wondering whether Becton Dickinson is starting to look like value at today’s share price, or if it deserves to be cheap, this breakdown will help you decide how the current market view stacks up against different valuation methods. The stock last closed at US$157.09, with returns of 0.5% over 7 days, a 5.1% decline over 30 days, and a year to date decline of 19.4% that leaves the 1 year return at a 2.3% decline and the 3 and 5 year returns at declines of 16.7% and 10.8%...

If you are trying to figure out whether Smithfield Foods is genuinely attractively priced or just riding a wave of optimism, the starting point is understanding what the current share price actually reflects. With the stock at US$29.16 and returns of 2.0% over 7 days, 20.2% over 30 days, 31.6% year to date and 54.8% over 1 year, many investors are asking whether the recent performance still lines up with underlying value. Recent coverage has focused on Smithfield Foods as a key player in the...

WeRide Inc. and its partners Grab Holdings and Uber Technologies have already launched public autonomous ride services in Singapore’s Punggol district and Dubai’s Jumeirah and Umm Suqeim areas, using WeRide GXR, Robobus and Level 4 Robotaxis under real-world operating conditions. These deployments highlight how WeRide is turning years of R&D and regulatory work into live, fare-charging services with new operator roles such as onboard Safety Operators and remote fleet monitoring staff. We’ll...

DigitalOcean Holdings (DOCN) is in focus after S&P Dow Jones Indices announced its removal from the S&P SmallCap 600 and addition to the S&P MidCap 400, a shift that often triggers meaningful index-linked trading. See our latest analysis for DigitalOcean Holdings. The index reshuffle comes at a time when DigitalOcean Holdings has a 1-day share price return of 3.22% and a 30-day share price return of 55.36%. The 1-year total shareholder return of 191.42% and 3-year total shareholder return of...